Norway launches massive colorectal cancer screening showdown: which test saves more lives?

NCT ID NCT01538550

Ongoing Prevention Sponsor: Norwegian Institute of Public Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large pilot study in Norway is comparing two common colorectal cancer screening methods—flexible sigmoidoscopy (a one-time scope exam) and biennial fecal immunochemical testing (a stool test)—to see which works best for the general population. Over 140,000 men and women aged 50-74 are taking part. The goal is to find the most effective way to reduce colorectal cancer deaths and improve screening services nationwide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: flexible sigmoidoscopy and fecal immunochemical test (iFOBT)
What this could lead to: If successful, this could help determine the most effective screening strategy for colorectal cancer, potentially reducing deaths from the disease on a national level.
What could go wrong: This is a pilot study comparing screening methods, not testing a new treatment. Results may not apply to other populations, and screening itself carries risks like false positives or complications from follow-up procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoma colorectal adenoma colorectal cancer colorectal neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL ADENOMAS COLORECTAL CANCER

Contacts and locations

Locations

Bærum County Hospital

Rud, 1309, Norway
Moss Hospital

Oslo, 1535, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.